Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms
- PMID: 21977068
- PMCID: PMC3183640
- DOI: 10.4103/1817-1737.84777
Effect of doxycycline in patients of moderate to severe chronic obstructive pulmonary disease with stable symptoms
Abstract
Background: The protease-antiprotease hypothesis proposes that inflammatory cells and oxidative stress in chronic obstructive pulmonary disease (COPD) produce increased levels of proteolytic enzymes (neutrophil elastase, matrix metalloproteinases [MMP]) which contribute to destruction of parenchyma resulting in progressive decline in forced expiratory volume in one second. Doxycycline, a tetracycline analogue, possesses anti-inflammatory properties and inhibits MMP enzymes.
Objectives: To assess the effect of 4 weeks doxycycline in a dose of 100 mg once a day in patients of moderate to severe COPD with stable symptoms.
Methods: In an interventional, randomized, observer-masked, parallel study design, the effect of doxycycline (100 mg once a day for 4 weeks) was assessed in patients of COPD having stable symptoms after a run-in period of 4 weeks. The study participants in reference group did not receive doxycycline. The parameters were pulmonary functions, systemic inflammation marker C-reactive protein (CRP), and medical research council (MRC) dyspnea scale. Use of systemic corticosteroids or antimicrobial agents was not allowed during the study period.
Results: A total of 61 patients completed the study (31 patients in doxycycline group and 30 patients in reference group). At 4 weeks, the pulmonary functions significantly improved in doxycycline group and the mean reduction in baseline serum CRP was significantly greater in doxycycline group as compared with reference group. There was no significant improvement in MRC dyspnea scale in both groups at 4 weeks.
Conclusion: The anti-inflammatory and MMP-inhibiting property of doxycycline might have contributed to the improvement of parameters in this study.
Keywords: Anti-inflammatory; C-reactive protein; doxycycline; dyspnea; matrix metalloproteinase; respiratory function tests.
Conflict of interest statement
Figures


Similar articles
-
Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study.Pulm Pharmacol Ther. 2019 Oct;58:101831. doi: 10.1016/j.pupt.2019.101831. Epub 2019 Jul 24. Pulm Pharmacol Ther. 2019. PMID: 31349003
-
Effects of doxycycline on local and systemic inflammation in stable COPD patients, a randomized clinical trial.Respir Med. 2016 Jan;110:46-52. doi: 10.1016/j.rmed.2015.10.009. Epub 2015 Oct 30. Respir Med. 2016. PMID: 26616678 Clinical Trial.
-
Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation.Clin Biochem. 2013 Nov;46(16-17):1678-82. doi: 10.1016/j.clinbiochem.2013.08.003. Epub 2013 Aug 15. Clin Biochem. 2013. PMID: 23954853
-
Doxycycline therapy for abdominal aneurysm: Improved proteolytic balance through reduced neutrophil content.J Vasc Surg. 2009 Mar;49(3):741-9. doi: 10.1016/j.jvs.2008.09.055. J Vasc Surg. 2009. PMID: 19268776 Clinical Trial.
-
Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.Treat Respir Med. 2004;3(4):247-68. doi: 10.2165/00151829-200403040-00005. Treat Respir Med. 2004. PMID: 15350163 Review.
Cited by
-
Targeted drug delivery to emphysematous lungs: Inhibition of MMPs by doxycycline loaded nanoparticles.Pulm Pharmacol Ther. 2016 Aug;39:64-73. doi: 10.1016/j.pupt.2016.06.004. Epub 2016 Jun 25. Pulm Pharmacol Ther. 2016. PMID: 27354173 Free PMC article.
-
Doxycycline host-directed therapy in human pulmonary tuberculosis.J Clin Invest. 2021 Aug 2;131(15):e141895. doi: 10.1172/JCI141895. J Clin Invest. 2021. PMID: 34128838 Free PMC article. Clinical Trial.
-
Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?Int J Chron Obstruct Pulmon Dis. 2017 Jun 23;12:1877-1882. doi: 10.2147/COPD.S138006. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 28694698 Free PMC article. Review.
-
Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.Am J Respir Crit Care Med. 2014 Jul 1;190(1):9-18. doi: 10.1164/rccm.201311-2106PP. Am J Respir Crit Care Med. 2014. PMID: 24713029 Free PMC article.
-
Cigarette Smoke Exposure Induces Neurocognitive Impairments and Neuropathological Changes in the Hippocampus.Front Mol Neurosci. 2022 May 17;15:893083. doi: 10.3389/fnmol.2022.893083. eCollection 2022. Front Mol Neurosci. 2022. PMID: 35656006 Free PMC article.
References
-
- Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. 2009. [Last accessed on 2010 Oct 15]. Available from: http:/www.goldcopd.com .
-
- Belvisi MG, Bottomley KM. The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): A therapeutic role for inhibitors of MMPs? Inflamm Res. 2003;52:95–100. - PubMed
-
- Reilly JJ, Jr, Silverman EK, Shapiro SD. Chronic Obstructive Pulmonary Disease. In: Casper DL, Braunwald E, editors. Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2006. pp. 1547–54.
-
- Betsuyaku T, Nishimura M, Takeyabu K, Tanino M, Venge P, Xu S, et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med. 1999;159:1985–91. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous